Literature DB >> 18095711

Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites.

Saurabh Aggarwal1, W Nathaniel Brennen, Thomas P Kole, Elizabeth Schneider, Ozlem Topaloglu, Melinda Yates, Robert J Cotter, Samuel R Denmeade.   

Abstract

A highly consistent trait of tumor stromal fibroblasts is the induction of the membrane-bound serine protease fibroblast activation protein-alpha (FAP), which is overexpressed on the surface of reactive stromal fibroblasts present within the stroma of the majority of human epithelial tumors. In contrast, FAP is not expressed by tumor epithelial cells or by fibroblasts or other cell types in normal tissues. The proteolytic activity of FAP, therefore, represents a potential pan-tumor target that can be exploited for the release of potent cytotoxins from inactive prodrugs consisting of an FAP peptide substrate coupled to a cytotoxin. To identify FAP peptide substrates, we used liquid chromatography tandem mass spectroscopy based sequencing to generate a complete map of the FAP cleavage sites within human collagen I derived gelatin. Positional analysis of the frequency of each amino acid at each position within the cleavage sites revealed FAP consensus sequences PPGP and (D/E)-(R/K)-G-(E/D)-(T/S)-G-P. These studies further demonstrated that ranking cleavage sites based on the magnitude of the LC/MS/MS extracted ion current predicted FAP substrates that were cleaved with highest efficiency. Fluorescence-quenched peptides were synthesized on the basis of the cleavage sites with the highest ion current rankings, and kinetic parameters for FAP hydrolysis were determined. The substrate DRGETGP, which corresponded to the consensus sequence, had the lowest Km of 21 microM. Overall the Km values were relatively similar for both high and low ranked substrates, whereas the kcat values differed by up to 100-fold. On the basis of these results, the FAP consensus sequences are currently being evaluated as FAP-selective peptide carriers for incorporation into FAP-activated prodrugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18095711      PMCID: PMC4696028          DOI: 10.1021/bi701921b

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  32 in total

Review 1.  Recombinant expression systems for the production of collagen.

Authors:  N J Bulleid; D C John; K E Kadler
Journal:  Biochem Soc Trans       Date:  2000       Impact factor: 5.407

2.  Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Patrick A McKee
Journal:  Arch Biochem Biophys       Date:  2006-11-17       Impact factor: 4.013

Review 3.  Tumor stroma as a regulator of neoplastic behavior. Agonistic and antagonistic elements embedded in the same connective tissue.

Authors:  R V Iozzo
Journal:  Lab Invest       Date:  1995-08       Impact factor: 5.662

Review 4.  Mass spectrometric approaches for the identification of gel-separated proteins.

Authors:  S D Patterson; R Aebersold
Journal:  Electrophoresis       Date:  1995-10       Impact factor: 3.535

5.  Expression and characterization of a low molecular weight recombinant human gelatin: development of a substitute for animal-derived gelatin with superior features.

Authors:  David Olsen; Jenny Jiang; Robert Chang; Robert Duffy; Masahiro Sakaguchi; Scott Leigh; Robert Lundgard; Julia Ju; Frank Buschman; Vu Truong-Le; Binh Pham; James W Polarek
Journal:  Protein Expr Purif       Date:  2005-04       Impact factor: 1.650

6.  Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease.

Authors:  M L Piñeiro-Sánchez; L A Goldstein; J Dodt; L Howard; Y Yeh; H Tran; W S Argraves; W T Chen
Journal:  J Biol Chem       Date:  1997-03-21       Impact factor: 5.157

7.  Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.

Authors:  Samuel R Denmeade; Carsten M Jakobsen; Samuel Janssen; Saeed R Khan; Elizabeth S Garrett; Hans Lilja; S Brogger Christensen; John T Isaacs
Journal:  J Natl Cancer Inst       Date:  2003-07-02       Impact factor: 13.506

8.  Biochemical characterization of human collagenase-3.

Authors:  V Knäuper; C López-Otin; B Smith; G Knight; G Murphy
Journal:  J Biol Chem       Date:  1996-01-19       Impact factor: 5.157

9.  Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.

Authors:  S R Denmeade; A Nagy; J Gao; H Lilja; A V Schally; J T Isaacs
Journal:  Cancer Res       Date:  1998-06-15       Impact factor: 12.701

10.  Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.

Authors:  Samuel Janssen; Carsten M Jakobsen; D Marc Rosen; Rebecca M Ricklis; Ulrich Reineke; Soeren B Christensen; Hans Lilja; Samuel R Denmeade
Journal:  Mol Cancer Ther       Date:  2004-11       Impact factor: 6.261

View more
  33 in total

1.  Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin.

Authors:  Aaron M LeBeau; W Nathaniel Brennen; Saurabh Aggarwal; Samuel R Denmeade
Journal:  Mol Cancer Ther       Date:  2009-05-05       Impact factor: 6.261

Review 2.  Mesenchymal stem cells and the embryonic reawakening theory of BPH.

Authors:  W Nathaniel Brennen; John T Isaacs
Journal:  Nat Rev Urol       Date:  2018-11       Impact factor: 14.432

Review 3.  The role of fibroblast activation protein in health and malignancy.

Authors:  Allison A Fitzgerald; Louis M Weiner
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

4.  Cancer-associated fibroblasts are positively correlated with metastatic potential of human gastric cancers.

Authors:  Kangkang Zhi; Xiaojun Shen; Hao Zhang; Jianwei Bi
Journal:  J Exp Clin Cancer Res       Date:  2010-06-08

5.  Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.

Authors:  Angela Pennisi; Xin Li; Wen Ling; Sharmin Khan; Dana Gaddy; Larry J Suva; Bart Barlogie; John D Shaughnessy; Nazneen Aziz; Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2009-04-08       Impact factor: 6.998

6.  Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.

Authors:  Sarah E Poplawski; Jack H Lai; Youhua Li; Zhiping Jin; Yuxin Liu; Wengen Wu; Yong Wu; Yuhong Zhou; James L Sudmeier; David G Sanford; William W Bachovchin
Journal:  J Med Chem       Date:  2013-04-29       Impact factor: 7.446

7.  Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice.

Authors:  Angélica M Santos; Jason Jung; Nazneen Aziz; Joseph L Kissil; Ellen Puré
Journal:  J Clin Invest       Date:  2009-11-16       Impact factor: 14.808

8.  Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers.

Authors:  Pui-Chi Lo; Juan Chen; Klara Stefflova; Michael S Warren; Roya Navab; Bizhan Bandarchi; Stefanie Mullins; Ming Tsao; Jonathan D Cheng; Gang Zheng
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

Review 9.  Stroma-epithelium crosstalk in prostate cancer.

Authors:  Yi-Nong Niu; Shu-Jie Xia
Journal:  Asian J Androl       Date:  2008-12-22       Impact factor: 3.285

10.  Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design.

Authors:  Kyung N Lee; Kenneth W Jackson; Simon Terzyan; Victoria J Christiansen; Patrick A McKee
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.